PR Newswire BiotechnologyCodex · 实盘不做把握 9/10
北京时间·🕒 发布 04:31:00时区推断·⟳ 抓取 04:33:49·⚡ 决策 07-30 04:34:21 +32s·89.8 天前
Vanda Pharmaceuticals宣布将于8月5日盘后发布二季度财报并召开电话会
本次只是财报发布时间和电话会安排公告，没有披露业绩、指引、订单、临床或监管新增事实。
📄 原文PR Newswire Biotechnology↗ 原文
Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026
Conference Call and Webcast to Follow WASHINGTON, July 29, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nas…
不做 Vanda Pharmaceuticals（VNDA.US）
仅为例行财报排期公告，未披露业绩或指引增量，方向中性且无可交易 edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-29 · 扩散 low · price-in 风险 high ↗
关键理由
- 本次只是财报发布时间和电话会安排公告，没有披露业绩、指引、订单、临床或监管新增事实。
- 事件不改变公司短期收入、利润、现金流或核心业务预期，无法形成同向交易催化。
主要风险
- 真正可交易信息要等2026-08-05盘后财报和管理层电话会披露后再重新研判。
原文全文
展开原文 · 1,717 字
Conference Call and Webcast to Follow
WASHINGTON, July 29, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2026 on Wednesday, August 5, 2026, after the market closes.
Vanda will host a conference call at 4:30 PM ET on Wednesday, August 5, 2026, during which management will discuss the second quarter 2026 financial results and other corporate activities. To participate in the conference call, please dial 1-888-596-4144 (domestic) or 1-646-968-2525 (international) and use passcode 1843107.
The conference call will be broadcast simultaneously and archived on Vanda's website, www.vandapharma.com. Investors should go to the website at least 15 minutes early to register, download, and install any necessary audio software.
A replay of the call will be available on Wednesday, August 5, 2026, beginning at 8:30 PM ET and will be accessible until Wednesday, August 12, 2026, at 11:59 PM ET. The replay call-in number is 1-800-770-2030 for domestic callers and 1-609-800-9909 for international callers. The passcode number is 1843107.
About Vanda Pharmaceuticals Inc.
Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.
Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
[email protected]
Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
[email protected]
SOURCE Vanda Pharmaceuticals Inc.
WASHINGTON, July 29, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2026 on Wednesday, August 5, 2026, after the market closes.
Vanda will host a conference call at 4:30 PM ET on Wednesday, August 5, 2026, during which management will discuss the second quarter 2026 financial results and other corporate activities. To participate in the conference call, please dial 1-888-596-4144 (domestic) or 1-646-968-2525 (international) and use passcode 1843107.
The conference call will be broadcast simultaneously and archived on Vanda's website, www.vandapharma.com. Investors should go to the website at least 15 minutes early to register, download, and install any necessary audio software.
A replay of the call will be available on Wednesday, August 5, 2026, beginning at 8:30 PM ET and will be accessible until Wednesday, August 12, 2026, at 11:59 PM ET. The replay call-in number is 1-800-770-2030 for domestic callers and 1-609-800-9909 for international callers. The passcode number is 1843107.
About Vanda Pharmaceuticals Inc.
Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.
Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
[email protected]
Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
[email protected]
SOURCE Vanda Pharmaceuticals Inc.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。